A prospective study on incidences of deep venous thrombosis in cholecystectomy patients between July 2011 to June 2012 by Elavarasan, S
1 
 
 
                          DISSERTATION 
 ON  
A PROSPECTIVE STUDY ON INCIDENCES OF DEEP VENOUS THROMBOSIS IN 
CHOLECYSTECTOMY PATIENTS BETWEEN JULY 2011 TO JUNE 2012  
. 
 Dissertation submitted to 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
In partial fulfilment of the regulations 
for the award of the degree of  
 
M.S. -GENERAL SURGERY- BRANCH – I 
 
                                                                                                   
 
THANJAVUR MEDICAL COLLEGE, 
THANJAVUR - 613 004. 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
          CHENNAI - 600 032. 
APRIL -2013 
2 
 
CERTIFICATE 
 
   This is to certify that this dissertation entitled ``A PROSPECTIVE STUDY ON 
INCIDENCES OF DEEP VENOUS THROMBOSIS IN CHOLECYSTECTOMY 
PATIENTS BETWEEN JULY 2011 TO JUNE 2012 ’’ is the bonafide original work of 
Dr.S.ELAVARASAN in partial fulfilment of the requirements for M.S. (General Surgery) 
Examination of the Tamilnadu Dr.M.G.R. Medical University to be held in APRIL  - 2013. 
The period of the study was from July – 2011 to June -2012.  
 
 
 
 
Prof.Dr.R. KARUNAHARAN                
MS.FICS.FIAGES, 
Unit Chief S-6 
Dept. Of General Surgery, 
Thanjavur Medical College, 
Thanjavur – 613004. 
Prof.Dr.V.BALAKRISHNAN. M.S., 
Head Of the Department, 
Dept. Of General Surgery, 
Thanjavur Medical College, 
Thanjavur – 613004. 
 
 
 
 
Prof.Dr. GUNASEKARAN. M.D.,DCH, 
DEAN, 
Thanjavur Medical College, 
Thanjavur – 613 004. 
3 
 
 
 
 
DECLARATION 
 
  I, Dr.S.ELAVARASAN, solemnly declare that the dissertation titled “A 
PROSPECTIVE STUDY ON INCIDENCES OF DEEP VENOUS THROMBOSIS IN 
CHOLECYSTECTOMY PATIENTS BETWEEN JULY 2011 TO JUNE 2012.” is a 
bonafide work done by me at Thanjavur Medical College, Thanjavur during July 2011 to June 
2012 under the guidance and supervision of Prof.Dr.T.KARUNAHARAN, M.S. 
FICS.FIAGES, Professor of general surgery, Thanjavur Medical College, Thanjavur. 
 This dissertation is submitted to Tamilnadu Dr. M.G.R Medical University 
towards partial fulfilment of requirement for the award of M.S. degree (Branch -I) in 
General Surgery. 
 
 
 
Place: Thanjavur. 
Date:      - 12 - 2012.                                             (Dr.S.ELAVARASAN.) 
        
  
 
 
 
4 
 
ACKNOWLEDGEMENT 
 I gratefully acknowledge and  my sincere thanks to Prof.Dr.GUNASEKARAN, 
M.D.DCH, Dean, Thanjavur Medical College, Thanjavur, for allowing me to do this 
dissertation and utilize the institutional facilities. 
 I am extremely grateful to Prof.Dr.V.BALAKRISHNAN, M.S., Professor and 
Head of  the  Department, Department  of  General Surgery, Thanjavur  Medical College, 
for his full-fledged support throughout my study and valuable suggestions and guidance 
during my study and my post graduate period. 
 I am greatly indebted to Prof.Dr.T.Karunaharan, M.S., FICS, FIAGES, my unit 
chief , who is my guide in this study, for his timely suggestion , constant encouragement 
and scholarly guidance in my study and my post graduate period. 
 I profoundly thank my respected Professors, Prof.Dr.T.Krishnamurthi,M.S, 
Prof.Dr.Maragathamani Ilangovan,M.S., Prof.Dr.D.Nagarajan,M.S., 
Prof.Dr.Elangovan,M.S., Prof.P.Rajagopal,M.S, Prof.Dr.P.Shanthini,M.S.,DGO, and 
Dr.R.Eganathan,M.S.D.A., (Registrar), for their advice, guidance and valuable criticism which 
enabled me to do this work effectively. 
     I would like to express my gratitude to Prof.Dr.k.Vijayalakshmi, M.D., DMRD., 
Professor and Head, Department of Radiology, and Prof.Dr.A.Srinivasan, M.D., Professor 
of Radiology for their immense help in the study which enabled me to complete this work . 
 My sincere thanks to assistant professors Dr.A.Michael,M.S.,Mch., 
Dr.S.Maruthudurai,M.S., Dr.K.Sathyabama,M.S, Dr.K.Anbarasan,M.S. 
Dr.Vanathi,M.S., and Dr.R.Ashokkumar,M.S., , for their motivation, encouragement and 
support. 
5 
 
  
I should always thank my senior and junior post graduates, CRRI’s who have 
helped me in numerable ways for my growth. 
A special mention of thanks to all the patients who participated in this study for 
their kind cooperation. 
 I would like to thank my colleagues and friends who have been a constant source 
of encouragement. 
 
  
6 
 
CONTENTS 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
SL. 
NO. 
TITLE PAGE NO. 
1 INTRODUCTION 1 
2 OBJECTIVES 2 
3 REVIEW OF  LITERATURE 6 
4 MATERIALS AND METHODS 3 
5 RESULTS OF THE STUDY 94 
6 ANALYSIS 95 
7 CONCLUSION 97 
8 BIBLIOGRAPHY 98 
9 PROFORMA ENCLOSED 
10 MASTER CHART ENCLOSED 
11 ABBREVIATIONS ENCLOSED 
12 PLAGIRISM REPORT ENCLOSED 
7 
 
Introduction  
    Deep venous thrombosis is a condition where there is development of 
thrombus in the vein of deep venous system, mostly affecting lower limbs.  
    Deep venous thrombosis is not a rare entity as we think. It is a much more 
common but often underestimated and under recognised. These are because of 
the lack of standardisation in all health facilities. That too in general surgery, 
where  it often goes unnoticed because of less suspicion. So to get an idea about 
DVT in patients undergoing open cholecystectomy, which is one of the common 
operations done in our hospital, I have done this study. 
Background  
     DVT causes lot of morbidity and mortality. It affects both patient and health 
faculty, in terms of time, money, materials and often lives in case of pulmonary 
embolism. To conclude the patient risk for developing DVT, who are undergoing 
open cholecystectomy in our institution, I have assessed the patients in a 
prospective manner. 
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Objective 
   1. To study the incidence of DVT in patients undergoing open 
cholecystectomy, who are otherwise free of obvious risk for DVT, for a period of 
one year from June 2011 to July 2012 in our general surgery department. 
2. To form a protocol for whom the pharmacological methods of thrombo 
prophylaxis are to be started. 
Why cholecystectomy in particular? 
1. Common major surgery in our hospital. 
2. Common risk factors to both like Fatty, fourty etc so Prone for DVT. 
3. Reverse Trendelenberg position for Cholecystectomy (as 40% of DVT starts on 
table itself) 
4. The immobilisation following surgery due to upper abdomen incision 
5. To prevent pulmonary embolism from its root level, as pulmonary embolism has 
high mortality. 
6. If the guidelines, suggested by this study are accepted it may be used for future 
protocols. 
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Materials and Methods 
All the patients planned for cholecystectomy were subjected to following 
investigations 
Radiological investigation 
• Doppler – for all patients  
• X ray chest / CT chest – if suspicion of PE 
Bio chemical investigations 
• Lipid profile 
• Complete hemogram 
• PT/INR 
• Liver function test 
• Renal function test 
• ESR 
History wise 
• h/o DVT/PE 
• Family history of connective tissue disorder 
• Cancer surgery 
• Immobilisation 
• OCP intake 
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• Post partum 
• h/o sepsis 
• varicose veins 
Clinically patient is examined in a symptom oriented manner.  
Study cohort 
Totally 68 open cholecystectomy done in out department. 
30 – Eligible after initial screening 
13 – Diabetic patients 
8 – Diabetic with hypertension 
2 – Septicaemia 
8 – Obesity (>30 BMI) 
2 – Altered liver function with low protein 
1 – Varicose veins 
3 – h/o unknown leg swelling, h/o local treatment and drug intake in last 3 
months 
1 – h/o DVT 
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Inclusion criteria 
The patients who are all undergoing open cholecystectomy, with following 
indications without any risk factor for DVT 
1. Calculus cholecystitis without septicaemia 
2. Cholelithiasis  
3. Acute cholecystitis with or without calculus without septicaemia 
4. CBD stone 
5. Mucocele Gallbladder 
Exclusion criteria 
1. Patients with DVT obvious risk factors  
2. Patients with Co morbid conditions known to cause DVT 
Key words 
• DVT – Deep Vein Thrombosis  
• PE – Pulmonary Embolism  
• VTE – venous thrombo embolism 
• GB – gall bladder 
• OC – open cholecystectomy 
• OC/CDL – open cholecystectomy with choledocholithotomy 
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Literature review 
DEEP VENOUS THROMBOSIS 
        One of the most common preventable cause of morbidity and mortality in 
hospitalised patients is deep venous thrombosis and it s complications like 
pulmonary embolism and post thrombotic syndromes. So it is essential to know 
about its incidence, aetiology, pathogenesis, pathology, clinical features, 
diagnosis, management and its sequalae.  
DVT is part of a spectrum of Venous Thrombo Embolism. The remainder being 
Pulmonary Embolism and post thrombotic sequalae. 
Recognition of its risk factors and early management also becomes a important 
aspect of its management.  
Always prevention is better than cure. So every aspect of DVT needs to be 
understood for its proper management. 
Rudolf Virchow’s pathophysiologic theory still holds the truth about its 
development. It is an area where much research is on now and needs still more 
light on it. A newest area is the response to thrombosis and its amplification 
response. It is clear now that DVT is a result of multiple factors interplay. And 
its management needs knowledge about that. 
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Incidence 
The exact data regarding the incidence of DVT in the post operative patients in 
India is still lacking. In different hospitals it is differing and uniformity is 
lacking. In USA 1 in 20 is the life time risk of a person developing DVT. Often it 
is a silent killer. Often the minor occurrence which is the most common thing 
goes unnoticed. 
Populations affected 
About 31% of hospital admissions both in medical and surgical wards develop 
some sort of this DVT. In this population the incidence varies with underlying 
disease, use of thrombo prophylaxis, the intensity of screening programmes, and 
the testing modality. For example in spinal injury patients with paraplegia or 
quadriplegia where the periodical screening is intense shows an 81% incidence. 
So suspicion on to the occurrence only can diagnose it.In patients of ICU either 
medical or surgical, the risk is high. In one study it was about 25 to 32%. But in 
patients receiving thrombo prophylaxis it was about 10 to 18%.  
In one interesting study showed that the duration of ICU stay is not related to the 
DVT incidence. Actually 64% of patients are developing this DVT after 
discharge only. So duration does not affect the incidence. 
Over all the spinal cord injury patients, neurosurgical patients, orthopaedic injury 
patients are at more risk of developing DVT than simply staying in ICU. 
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Recurrence 
Although being described as an acute event, often it recurs till the cause is 
completely removed. Often it is not a simple task. And these patients are more at 
risk of developing PE than just the recurrent DVT alone.  
A 7-day case fatality study showed that recurrent PE is more common than 
recurrent DVT. 
Mortality 
A 30 year data showed a 26% incidence of PE in one autopsy series. Out of it 
only 9% were fatal. So it comes around 1% incidence of PE and 0.36 % of death 
due to PE. 
Risk factors 
Primary or Idiopathic DVT – no identifiable risk factor  
Secondary DVT – in the background of known DVT risk factors  
For hospital based studies – availability of objective diagnostic tests, high 
incidence among these patients, existence of many clinical trials made easy 
identification of these risk factors. 
But for population based studies – less well defined risk factors and criteria’s. 
In patients (IP) vs. out patients (OP) – different risk factors 
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OP patient risk factor – malignancy, surgery, trauma within previous 3 months – 
significant risk factors. 
Risk increases as the no of risk factors increases. Three or more risk factors 
increase significant chances of DVT. The relative risk of developing DVT from 
2.4 in those with one risk factor to greater than 20 in subjects with 3 or more risk 
factors. 
Heit and colleagues – older age, male gender, surgery, trauma, hospital or 
nursing home confinement, malignancy, neurologic disease with extremity 
paralysis, placing central vein catheter or transvenous pacemaker, history of 
superficial thrombo phlebitis, and varicose veins. 
Among women – pregnancy, OCP use, HRT,  
Predictors of recurrent DVT – older age, obesity, malignancy, extremity paresis. 
Risk factors in children – local infection and trauma, immobilization, inherited 
hypercoagulable states, catheters, severe oncologic and infectious diseases and 
thrombophilia.  
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Risk Factor for DVT or PE Odds 
 Ratio 
Hospitalization   
With recent surgery  21.72 
Without recent surgery  7.98 
Trauma  12.69 
Malignant neoplasm   
With chemotherapy  6.53 
Without chemotherapy  4.05 
Previous central venous catheter or pacemaker 5.55 
Previous superficial vein thrombosis 4.32 
Neurologic disease with extremity paresis 3.04 
Varicose veins   
Age 45 yr  4.19 
Age 60 yr  1.93 
Age 75 yr  0.88 
Congestive heart failure   
Thromboembolism not categorized as a cause of death at  post-
mortem examination 9.64 
Thromboembolism categorized as a cause of death at post-mortem
examination 1.36 
 
Age 
Old age – high incidence. A community based study showed increasing 
incidence of DVT from 0 incidences in childhood to 7.65/1000 in male and 
8.22/1000 in female older than 80 years.  
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Rosendaal study – 0.006/1000 in younger than 14 years, increases to 0.7/1000 in 
40 to 54 years old people.  
Hansson and colleagues study – objectively documented thrombo embolic events 
increased from 0.5% at 50 years to 3.8% at 80 years. 
Multifactorial influence of age on DVT incidence.  
The number of thrombotic risk factors increase with age – 3% DVT incidence in 
<40 years aged hospitalised patients compared to 30% in >40 years aged 
patients. 
The number of risk factors required for precipitating the thrombotic event is 
reduced as age advances as the individual factors are getting strengthened.  
As the age advances the levels of thrombin activation markers increased like P 
selectins, tissue factors and procoagulant micro particles. 
Soleal veins – anatomically changes are occurring in favour of DVT as age 
advances. 
Low incidences of DVT in hospitalised children are due to early ambulation and 
early discharge. Also the diagnosis is often not considered in the paediatric age 
group.  
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Immobilization 
Soleal vein stasis behind the valve cusps is exacerbated by both immobilization 
and old age. Incidence parallels the duration of immobility. An increase in first3 
days and a rapid rise to very high levels after 2 weeks. Preoperative 
immobilization doubles the chance of post operative DVT risk. Paralysis patients 
are at increased risk of developing the DVT than non-paralysed. Average is 
about threefold risk. 
Travel 
Economy class syndrome – prolonged travel in sitting in a cramped position. 
But till now, no rheological or thrombotic changes have been demonstrated. 
WHO 2001 consensus  
• An association probably exists between air travel and venous thrombosis 
• Only a small risk and affects mainly the persons with additional risks 
• All forms of travels are associated with risk 
• Available evidence does not give the incidence.  
  History of venous thrombo embolism 
Risk is higher in Idiopathic DVT patients where the definitive aetiology could 
not be established. Fibrous remnants following DVT play the crucial role in DVT 
recurrence. Other factors like disordered venous hemodynamic, residual damage 
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to venous walls, abnormalities of coagulation and fibrinolytic mechanisms are 
also important. However primary hyper coagulability appears to have a 
significant role in many recurrences. 
Simioni and associates reported the recurrence in factor V leiden mutation people 
was about 40% at 8 years follow up. 
Den heijer and collegues reported that 17% of recurrence is due to 
hyperhomocystinemia.  
Malignancy 
About 20% of newly diagnosed DVT are associated with malignancy.  
Malignancy increases the risk of DVT, a fourfold compared to normal 
population. 12 to 17% of times the occult malignancy is associated with DVT, 
where it is considered as idiopathic and often unnoticed. In addition, in patients 
of recurrent DVT, the incidence of malignancy, in one series is about 17%. 
The factors in malignancy responsible for DVT are venous compression by 
tumour, immobility, thrombocytosis caused by tumour, chemo radiation, central 
lines, and tumour products like cytokines, procoagulant and inhibitors of 
fibrinolytic system. 
The tumours known to cause DVT are pancreatic malignancies, kidney, ovary, 
and lung and stomach malignancy. Tissue Factor (TF) is the reason for tumour 
cell directly activating the coagulation saccade as it binds the VII and VII a 
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factors and activating the cascade. Cancer Procoagulant (CP) is a other reason for 
DVT in malignancy, as it directly activates factor X, independent of factor VIIa. 
CP is mainly indicated in myelogenous leukaemia’s, as the reason for DVT. Ib 
and IIb/III glycoprotein’s are also being identified as being released from 
tumour. It causes platelet activation and aggregation. VEGF, TNF-alpha and IL-1 
are also released from tumours which are also the reason for induction of TF on 
vascular endothelium. Also the IL-1 and TNF down regulate the expression of 
thrombomodulin on endothelial surface. It also stimulates the production of 
plasminogen activator inhibitor of fibrinolysis. 
The markers of activated coagulation are persistently elevated in malignancy 
patients. Fibrin peptide A levels reflects the tumour activity. In that it is kept on 
elevation in malignancy not amenable to heparin, indicating that these DVT are 
refractory to anticoagulants. The surgical procedure for malignancy and also the 
chemotherapy for these malignancies are known to risk DVT in these patients.  
Preoperative elevation of thrombin – thrombomodulin complex is associate with 
7.5 fold increase of post operative DVT.  
Reported incidence of DVT following treatment is 6% in non Hodgkin 
lymphoma patients and 17.5% in breast cancer patients and germ cell cancer 
patients about 11%. The potential mechanism for these DVT include direct 
endothelial injury, induction of a hyper coagulable state,  reduced fibrinolytic 
activity, tumor cell lysis, and use of central vein catheters. Also some 
21 
 
chemotherapeutic agents are known to activate the coagulation cascade in these 
patients, which adds further risk. 
Surgery 
The high incidence in post operative patients, hospital stay, investigations and 
specialist availability, all these made a better understanding of this condition.  
The factors like age of patient, co morbid thrombotic conditions, surgical trauma 
extent, timing of surgery and post operative immobilization increases the risk of 
DVT. 
The overall incidence of DVT in general surgical patients is 19%. 
Based on these factors the patients are categorised as follows 
categoryCharacteristics 
Low  Age <40 years, no other risk factors, uncomplicated abdominal /  
 thoracic surgery 
Age >40 years, no other risk factors, minor elective abdominal/ 
thoracic surgery <30 minutes,  
Moderate Age >40 years, abdominal/thoracic surgery >30 minutes 
High  History of recent thromboembolism, abdominal or pelvic procedure for 
malignancy, major lower extremity orthopaedic procedure. 
 
Actually the process of DVT starts in operating table itself and it fully getting 
established over next 3- 5 days. This process does not stop at discharge and 
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actually continues beyond also. The re admission after previous discharge 
actually doubles the risk as the previous risk is getting amplified by this 
admission. All the components of Virchow’s triad are present in post operative 
patients. Perioperative immobilization leads to venous stasis. Extensive 
endothelial injury is also present. Because of extensive TF release from surgical 
trauma, there is a hypercoagulable state in this age group.  So there is every 
chance for DVT to develop waiting the inciting event. 
“Post operative fibrinolytic shutdown” increased levels of PAI-I in early post 
operative period leads to a thrombogenic state. So it leads to a conclusion that 
levels of PAI-I in early post operative period is a marker of DVT risk. 
Trauma 
Another group of people, where there is a definite risk of DVT in spite of all 
measures.  
Olmsted county study – 13 fold increased risk of DVT in trauma patients.  
Risk factors implicated 
• Age 
• Blood transfusion 
• Surgery 
• Bone fracture 
• Spinal cord injury 
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• TF release 
• Significant period of immobility 
• Paralysis 
• Venous injury 
• Prolonged hospital stay 
• Dehydration chances 
• Multiple drugs 
Inherited thrombophilia 
Prothrombin gene mutation  
Guanine to adenine transition at 20210 nucleotide – poort and associates in 1996. 
87% of times they have 115% of Prothrombin levels. This mutation is rare in 
Asian or African population. In heterozygous mutation the risk is threefold and 
in homozygous it increases further. In 1 to 10% of cases there is co-inheritance 
of Factor V Leiden mutation. 
Factor V Leiden mutation 
Replacement of arginine with glutamine at 506 positions is called as this 
mutation. The mutated factor is resistant cleavage by APC. So more amount of 
thrombin is generated. Autosomal dominant mode inheritance.In heterozygous 
states the risk increases by 7fold but in homozygous 80 fold.  
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Protein C 
It is a vitamin k dependant serine protease that inactivates factor X and thrombin.  
Deficiency can be both inherited and acquired. Type I – heterozygous 
inheritance – Autosomal dominant inheritance-reduction of both antigenic and 
functional level. Type II – antigen level is normal but the functional level 
reduced. Acquired deficiency occurs in acute thrombotic events, liver disease, 
renal disease, disseminated intravascular coagulation, haemolytic uremic 
syndrome, chemotherapy with asparginase, thrombotic thrombocytopenic 
purpura and acute infection. 
Protein S 
It acts as a co factor for protein C action.  Autosomal dominant inherited 
deficiency occurs. More common than protein C deficiency. 
Type I – quantitative deficiency 
Type II – qualitative 
Type III – mutation that increases the affinity of protein S for C4b-binding 
proteins. 
Acquired deficiency – disseminated intravascular deficiency, diabetes mellitus, 
pregnancy, oral contraceptive use, nephritic syndrome, liver disease and essential 
thrombocythemia. 
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Antithrombin 
A glycoprotein product of liver, inhibits thrombin and factors Xa,IXa,Xia, and 
XIIa. Heparin augments the action of this.  Deficiency is inherited as Autosomal 
dominant inheritance. Clinically manifests as thrombosis of ilio femoral veins, 
upper limb deep veins, mesenteric veins, vena cava, renal veins and retinal veins.  
Also it may present as cerebral venous thrombosis and budd-chiari syndrome. 
Pregnancy 
6 to 10 fold increased risk. Risk of thrombosis is 2-3 times more in puerperium 
compared to pregnancy. Risk is equal throughout all the three trimesters. 
Reasons 
• Impaired venous flow due to obstruction 
• Transient hypercoagulable state 
• Increased fibrinogen level 
• Acquired functional resistance to APC 
• tpa levels reduced. PAI 1&2 increased. 
 Caesarean increases the risk of DVT compared to normal delivery.  Other risk 
factors for puerperal DVT are maternal age advancement, suppression of 
lactation, hypertension, and assisted delivery but not with the number of 
pregnancies. 
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Oral contraceptives and Hormonal therapy 
An independent risk factor. Its OR is 3.8 to 11. 1/4th of idiopathic DVT in young 
women is due to OCP, which is often unnoticed. The risk is decreased after the 
withdrawal of OCP. When it is taken by the patients who underwent surgery or 
associated with inherited disorder of coagulation, the risk increases. 
Risk is related to dose of estrogen and type of progesterone. Preparations 
containing less than <30 to 50 micro g of estrogen carries less risk. Third 
generation contraceptives containing progestins are associated with two fold risk 
of DVT. Estrogenic compounds when used for suppression of lactation, cancer 
prostate, and post menopausal replacement also risk DVT. Hormone replacement 
therapy has DVT risk, which is more in first year of treatment, and due to 
adaptation it decreases subsequently. Possible mechanisms are decrease in PAI-I, 
increase in blood viscosity, fibrinogen, plasma levels of factors VII and X, 
platelet adhesion and aggregation. 
Blood group 
A group is associated with 1.41 times more risk of DVT compared to other 
groups. The safest blood group is O group, due to lower levels of vWF in 
epithelial surface. 
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Central venous catheters 
They are used mainly for hemodynamic monitoring, infusion lines and 
pacemakers. They are mainly associated with upper limb DVT. Incidence varies 
from 28% for subclavian canulation to 12% in femoral vein canulation as it is 
occurring in cases of trauma. Possible mechanisms are vascular injury and stasis. 
The catheter material whether Teflon or heparin bonded material is also a 
deciding factor. Catheter diameter, number of venipuncture attempts, duration of 
catheter placement and composition of the infusate. 
Inflammatory bowel disease 
Patients with crohns disease were reported to have 31.4% and 10.3% of DVT and 
PE. For ulcerative colitis it is 30 and 19.8%. More in patients with active disease. 
It also depends on the extent of disease, where the extensive disease persons will 
have repeated DVT episodes. Possible mechanisms are thrombocytosis, elevation 
of factors V, VIII, and fibrinogen during active episodes, depressed levels of 
Antithrombin, elevated PAI-I values, and presence of anti-cardiolipin antibodies. 
And also possibly endotoxin induced monocyte activation. 
Systemic lupus erythematosus (SLE) 
Multiple arterial and venous thrombosis, recurrent abortion, thrombocytopenia, 
and neurologic disorders are part of its spectrum. Lupus anticoagulant and 
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anticardiolipin antibodies may be seen in SLE. Lupus anticoagulant has a six fold 
and anti cardiolipin antibodies have two fold risk of DVT.  
Varicose veins and superficial thrombophlebitis 
An independent risk factor. ORs of 3.6 to 6.9. In Young patients with 
varicosities, it constitutes an important risk factor. 
Iliac vein compression 
A congenital risk factor. 
Compression of left iliac vein by right iliac artery and fifth lumbar artery was 
identified by May and Thurner. 
Left lower extremity venous hypertension with or without iliofemoral DVt is 
known as May and Thurner syndrome.  
Cockett syndrome – acute phase of ilio femoral DVt secondary to compression 
of the iliac vein with the long term Chronic Venous Insufficiency. 
May Thurner syndrome 
These syndromes are occurring in young to middle aged women, also after 
multiple pregnancies. Patients present with left leg pain and swelling. In 
asymptomatic population CT imaging shows compression of left iliac vein is 
35%. Out of it 24% is associated with more than 50% obstruction. 
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Upper extremity compression 
It is more common in those patients who has indwelling central line, canulation 
and pace makers in situ for to get DVT due to direct injury to vessel wall, and 
stasis due to canula. 
Also in patients of thoracic outlet obstruction where there is risk of vessel wall 
injury and stasis, post stenotic dilatation also increases the risk. 
Paget – schrotter syndrome – primary axillary – subclavian vein thrombosis by 
repetitive physical activity of upper limb and injury to subclavian vessel and 
axillary vessel. It is more common in patients like base ball players, swimming, 
and weight lifting.  It will present with arm swelling, cyanotic discoloration, 
dilated veins of limb, fatigue, heaviness or pain with use.often the patient is 
young and healthy excepting this. 
Popliteal vein entrapment 
Anatomic anomalies like medial or lateral head of gastrocnemius is associated 
with Popliteal vein and sometimes artery also entrapment. Bone tumours and 
hypertrophied fibrous fascia also are the causes. Venous entrapment is more 
common in females. The typical patient will be young adult, with signs of 
chronic venous insufficiency including leg swelling, varicosities, skin changes 
and occasionally DVT. 
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Venous aneurysm 
These dilatations are associated with high flow states, trauma and additional 
congenital malformations. Popliteal solitary aneurysms are associated with PE 
usually as well as venous insufficiency. 
Unlike arterial aneurysms, the risk of rupture is very low or negligible. 
IVC aneurysms are associated with rupture, embolism, and thrombosis. But 
thoracic aneurysms are associated with benign course. 
Other risk factors 
IVC anomalies 
Either hypoplasia or absence of IVC, which is usually happening at 6 -8th week 
of gestation is associated with high risk of DVT. It is postulated to be due to, 
stasis in collaterals, intimal underdevelopment and associated hyper viscosity. 
Often the patients are very young to present with. In any adult younger than 30 
years with bilateral DVT should be suspected of having these. 
Obesity 
In post menopausal women with BMI 25 to 30 kg/m2 are associated with higher 
risk. But in younger age groups it is not an independent risk factor but in 
presence of other inciting events the risk is high. 
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Congestive heart failure 
Primarily due to venous stasis, when it is associated with other risk factors the 
risk of DVT increases. 
Systemic hyper coagulability 
In patients of myocardial infarction and post thrombolytic patients, the 
hypercoagulability as part of physiologic response is associated with DVT. 
Pathophysiology 
Virchow’s triad 
The three components 
• abnormalities in blood flow 
• abnormalities in blood 
• vascular injury 
These parameters are subsequently be refined as follows 
• flow abnormalities determine the location of DVT 
• abnormalities in blood may be either coagulation abnormality or fibrinolytic 
system abnormality 
• biologic injury to endothelium is more important than gross injury 
However the origin of DVT is Multifactorial.  
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Gwendylen Stewart – relation between thrombosis and inflammation. This 
relationship is more important in the thrombogenic process and evolution of 
thrombus. Mechanical venous injury plays an important role in direct venous 
trauma, hip arthroplasty and central venous catheters.  Overt endothelial injury is 
not a significant factor in development of DVT in the absence of other stimuli. 
Endothelium and Haemostasis 
Normal endothelium provides a vasodilatory and local fibrinolytic environment. 
It also inhibits coagulation, platelet adhesion, platelet activation, inflammation, 
and leukocyte activation.  
Possible mechanisms are  
• thrombomodulin and protein c production 
• expression of heparin and dermatan sulphate 
• expression of tissue factor pathway inhibitors 
• Production of tissue and urokinase type plasminogen activators. 
• It also produces NO, prostacyclin, IL-10 
During the states of disturbance of endothelium, pro inflammatory and pro 
thrombotic states occur. PAF and endothelin -1 released by endothelium causes 
vasoconstriction. vWF, TF, PAI-I and activated factor V cause thrombosis.  In 
inflammation or injury there is also up regulation of P – selectins and E-selectins. 
This sets the stage for DVT. 
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Inflammation and Thrombosis 
In inflammation following changes are happening 
• TF increases 
• Platelet activity increased 
• Level of fibrinogen increased 
• Phosphatidyl serine expression increased 
• PAI-I level decreases 
• Thrombo modulin and Protein C level and function decreases 
Selectins are the first upregulated glycoproteins which increases in inflammation. 
Venous stasis and ischemia causes upregulation of P selectin and this selectin 
causes MP expression which leads to prothrombotic stage and eventually DVT.  
The receptor for selectin PSGL-1 is highly expressed in leukocytes , platelets and 
MP’s. 
P -selectin   and receptor interaction -> thrombogenic MP release from leukocyte 
-> platelets also releases the same-> TF over expression->Phosphatidyl serine 
rich anionic surface exposed-> coagulation cascade activation. 
In DVT, MP’s have found to be elevated. These inhibit fibrinolysis. These MP’s 
are co localised in thrombus, they not only prothrombotic but also inhibit 
fibrinolysis. 
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Plasminogen system 
It is the main fibrinolytic enzyme; with its substrates are fibrin, fibrinogen and 
other coagulation factors.   It also interferes with vWF mediated platelet 
adhesion. Its activators are being inhibited by PAI-I. PAI-I is synthesized by 
liver and endothelium. It is stabilised by its binding with vitronectin.  Thrombus 
resolution and vein wall remodelling. Profibrotic growth factors, deposition of 
collagen, MMP expression and activation – all these leads to resolution. The 
order of changes happening in thrombus as follows 
Neutrophil infiltration of thrombus-> enzymes released from Neutrophil causes 
fibrinolysis and collagenolysis-> monocyte replacing Neutrophils (levels 
correlate with MCP-I) -> depletion of CC receptor -2 -> late impairment of 
thrombus resolution (-> exogenous interferon can fully resolve thrombus.) 
The changes in the vein wall are as follows 
Elastinolysis -> MMP 2 & 9 elevation-> early vein wall collagenolysis in 7 days-
> elevated levels of TGF-B, IL-13and MCP -1. -> Fibrosis with increase in 
collagen 1 and 3 
So to conclude inhibition of inflammation decreases vein wall fibrosis. Inhibition 
of P-selectin decreases the vein wall fibrosis. 
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Stasis 
Most of thrombosis occur in low velocity flow areas like Soleal veins and post 
valve areas.  
Possible mechanism is the hypoxia caused by this inadequate flow causes 
endothelial damage->cytokine production-> expression of leukocyte adhesion 
molecule-> adhesion and migration of leukocyte.  
Stasis also allows accumulation of activated coagulation factors-> thrombosis 
Stasis causes consumption of inhibitors of coagulation -> thrombosis 
In large veins, due to low surface to volume, inhibitory effects are less prominent 
by endothelium. So it promotes thrombosis.  But stasis appears to be an 
inadequate source for thrombosis. And it is a permissive factor only in many 
studies. It indicates it precipitates much of the existing risk factors. 
Activation of coagulation 
It is the critical step in the pathogenesis of DVT. The balance between the pro 
and anti factors only maintains the equilibrium. When the homeostasis is 
disturbed to coagulation side DVT occurs. Individual factor assay is not much 
helpful. But the following factors are found to be help full in assaying 
• Prothrombin fragment F1+2, it is generated by factor Xa in the cleavage of 
Prothrombin to thrombin 
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• Fibrinopeptide A , formed in the conversion of  fibrinogen to fibrin 
• Thrombin – anti thrombin complex 
• Fibrin degradation products like fragment D and E. But clinically only the D 
fraction is being used. D dimer assay used in these settings predict the ongoing 
risk for recurrent thromboembolism. 
Even though only activated coagulation system cannot cause DVT. In the 
presence of the endothelial injury and stasis only it can cause the thrombosis. 
Otherwise it is insufficient to cause DVT. So it is a multi factorial causation than 
a simple factor. 
Natural history 
Thrombus evolution as Determined by Non-invasive studies. The balance 
between organization, thrombolysis, propagation, and re-thrombosis determines 
the outcome after thrombosis.  The most important outcome after thrombosis is 
recanalization and recurrent thrombosis. Impedence plethysmography, a non 
invasive test detected the improvement after thrombosis. But it cannot 
differentiate between recanalization and collateral development. Venous duplex 
ultrasonography can be used for the same purpose and it can able to differentiate 
between these two. Van Ramshorst and associates – exponential decrease in 
thrombus load over the first 6 months after bypass surgeries. That too the process 
occurs in first 6 weeks.  
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Recanalization begins early after an acute episode of acute DVT that is within 6 
weeks, but often it completes within 3 months of the events. Complete thrombus 
resolution occurs in 56% of times in 9 months. Recurrent thrombotic events often 
compete with recanalization. So there is often both processes are undergoing. 
More proximal the DVT more chances of getting PE in these patients. Proximal 
propagation also occurs in this group of patients. Propagation to new segments in 
the ipsilateral limb tends to occur at the earliest within 40 days of diagnosis, but 
contralateral limb extension occurred only rarely.  
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Complications 
Pulmonary embolism 
The most devastating complication of acute DVT is PE.  
But it is usually silent, but when it floridly occurring it is fatal. Asymptomatic 
presentation can be up to 80%. Approximately 90% of PE is caused by proximal 
lower extremity venous thrombosis. Some autopsy series states that the 
combination of DVT and PE is 1.8 times more common than DVT alone. 
Modern investigations increased the detection of asymptomatic PE when it is 
done for some other indication. Symptomatic presentation of PE is not only 
dependant on amount of vessel occlusion, but also the cardio respiratory reserve 
of the patient. The risk of death in symptomatic PE is 18 fold higher than DVT 
patient alone. But in occasional cases the first presentation may be sudden death 
also. 
Pulmonary hypertension 
It is also called as Chronic Thrombo Embolic Pulmonary Hypertension 
(CTEPH).       0.1to 0.5% of individuals who recovered acute episode of PE 
develop this complication. Its presentations can vary from progressive exertional 
dyspnoea, Right Ventricular Failure features, edema, chest pain, light 
headedness, and syncope. But many patients can present with this without any 
history of PE. So it is appropriate to try the surgical treatment when it is 
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indicated than medical management which is associated with poor outcomes. So 
either pulmonary thromboembolectomy or pulmonary endarterectomy can be a 
appropriate option. 
Post thrombotic syndrome 
A less common complication than PE, but a significant complication.  
It may present as pain, edema, heaviness or hyper pigmentation but severe 
manifestation occurs only in 7 to 23%. In 4 to 6 % of patients, ulcers may 
develop. But often the stasis changes are more prevalent.  
One of the severe complications is ambulatory venous hypertension. It is 
associated with valvular reflux, persistent venous obstruction and the anatomic 
distribution of these abnormalities.  
Valvular reflux is an important complication of DVT. About 33% of initially 
thrombosed segments show evidence of reflux on duplex ultrasonography one 
year after the event. 
A natural mechanism which causes the thrombus organization will not to affect 
the valve cusp. It is separated from cusp by a clear zone of fibrinolysis caused by 
cusp endothelium to protect it from process. But it fails in 10% of individuals.  
There are several factors to influence the outcome after thrombosis like rate of 
recanalization, extent of reflux, anatomic distribution of reflux and obstruction 
and recurrent thrombotic event. 
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Also a high body mass index is also a risk factor for post thrombotic syndrome. 
Reflux is associated with long time for recanalization, and recurrent thrombo 
embolism. The incidence of venous stasis syndrome continues to rise for 20 
years after VTE. It is shown in so many studies. 
Prandoni and colleagues – post thrombotic syndrome 22.8% after 2 years, 28% 
after 5 years and 29.1% after 8 years. 
Mohr and associates- venous stasis syndrome is three time more common in 
proximal DVT than distal type. 
Mortality 
Usually DVT is associated with co morbid conditions. So the patient is so fragile 
and cannot withstand this stress.  
Kniffen and associates – 21% mortality in first year 
Early mortality is very high in upper extremity DVT patients. These patients tend 
to be more fragile due to usually metastatic malignancy. Six month mortality is 
48% in upper extremity DVT compared to 13% in the lower extremity DVT 
patients. 
Calf vein thrombosis 
It is a condition where isolated occurrence of thrombosis in calf muscles. This 
thrombus recanalize early. 50 % reduction occurs in 1 month and complete 
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recanalization in 1 year. Incidence of reflux is also low. One third to one fourth 
patients may develop proximal propagation. 10 % of patients may develop PE. 
Post thrombotic syndromes also can develop in these patients like pain, swelling 
and recurrent thrombosis. These muscular vein thromboses should be treated 
with anticoagulation for at least 15 to 30 days and longer than this in high risk 
patients. 
DEEP VEIN THROMBOSIS: CLINICAL AND DIAGNOSTIC 
EVALUATION 
DVT should be diagnosed timely and accurately as the consequences of late 
diagnosis may be fatal. It may result in pulmonary embolism, post thrombotic 
syndrome and even death. In many cases the clinical presentation of DVT may 
not be typical.  Newer diagnostic techniques now make the diagnosis of DVT 
earlier and easier. 
CLINICAL FINDINGS 
Findings commonly seen are pain, fever, edema, tenderness, pain on dorsiflexion 
of foot (Homan’s sign) and peripheral cyanosis. 50% patients may not have the 
typical signs and symptoms. 
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RISK FACTORs 
Risk factors will be present in most cases. They include age, prolonged bed rest, 
malignancy, trauma, pregnancy, and other factors.80% of patients will have at 
least one risk factor. 
Wells Prediction Rules 
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DIAGNOSTIC TESTS 
VENOGRAPHY 
It was historically the gold standard for the diagnosis of acute DVT, but it has 
been replaced by newer less invasive techniques. It use has been limited as it 
involves risk of phlebitis, nephrotoxicity, allergic reactions, cost and need for an 
adequate intravenous access. 
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DUPLEX ULTRASONOGRAPHY 
It has almost completely replaced venography as the diagnostic test of choice for 
the detection of DVT. Its advantage is that it is non invasive, lack of radiation, 
portability and cost effectiveness. 
DIAGNOSTIC CRITERIA 
It includes assessment of venous compressibility and intra luminal echoes using 
the B-scan image, luminal colour filling using colour Doppler, venous flow 
characteristic using Doppler. Of these venous incompressibility is the most 
widely used objective criterion. Incompressibility has excellent sensitivity and 
specificity for the detection of proximal DVT. The use of colour flow imaging 
has also improved the accuracy of detecting isolated thrombi below the level of 
knee. 
REPEAT ULTRASOUND STUDIES 
Studies have shown that repeat duplex ultrasound help to distinguish high risk 
patients who may benefit from vena caval filter placement. The consensus from 
different studies has been to repeat ultra sound studies when clinical symptoms 
persist despite a negative initial examination. 
D-DIMER 
 D-dimer is the degradation product of cross linked fibrin by plasmin. Tests are 
based on the development of monoclonal antibodies capable of differentiating 
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the degradation products of fibrin and fibrinogen. The presence of D-dimer 
reflects the presence of intravascular fibrin and it is sensitive for the diagnosis of 
thromboembolism. The sensitivity for the diagnosis of DVT is as high as 97%, 
but the specificities are as low as 35%. Elevated D-dimer values are also seen in 
disseminated intravascular coagulation, malignancy, post operative states, 
infection, preeclampsia and recent trauma. The specificity of D-dimer 
measurements diminishes with age. 
 ASSAYS 
Four methods of measuring D-dimer levels in blood are currently available: 
Conventional membrane ELISA, Micro plate ELISA, Latex agglutination and 
whole blood agglutination assays.  
ELISAs may have higher sensitivity but agglutination assays may have higher 
specificity. Several rapid semi-quantitative assay results can be reported in 
1hour, with sensitivities equivalent to those of ELISA. These rapid quantitative 
assays appear to have the best combination of convenience, sensitivity and 
specificity. 
ACCURACY 
Due to the high sensitivity of this test, it is possible to exclude a diagnosis of 
DVT on the basis of negative result. But due to the low specificity a positive D-
dimer assay will need another confirmatory testing. 
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LIMITATONS 
D-dimer levels are falsely elevated in malignancy, pregnancy, recent post 
operative state and total bilirubin level more than 2mg/dL. 
Despite its limitations, D-dimer is a useful tool to rule out DVT as long as the 
threshold is kept low so as to keep the sensitivity high. 
MAGNETIC RESONANCE VENOGRAPHY (MRV) 
MRV has been developed for the imaging of venous circulation. It takes 
advantage of the ability of magnetic resonance to distinguish stationary from 
moving signals and it has gained momentum in recent years for the detection of 
DVT. 
It is less costly than contrast venography an also overcomes the limitations of 
contrast – enhanced ultrasound and Impedence plethysmography. Since MRV 
directly visualizes the thrombus, even non-flow- limiting thrombi can be 
detectable.MRV can also be able to detect thrombi proximal to the inguinal 
ligament, an area that has been problematic for duplex ultrasound in the past. 
Also in contrast to contrast ultrasound, MRV results are independent of 
technician availability and experience. 
Different types of MRV protocols have been used for the detection of DVT, 
including non- contrast-enhanced MRV techniques like time of flight (TOF) and 
phase contrast as well as contrast enhanced MRV (CEMRV). TOF MRV and 
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phase contrast MRV rely on low- related enhancement and velocity shifts to 
provide signals from flowing blood. For magnetic resonance arteriography, 
CEMRV provides rapid three- dimensional sequences after timed injection of a 
contrast agent and post processing algorithms to remove the arterial signal. Post 
processing techniques allow the creation of three – dimensional images 
analogous to those obtained with conventional venography. 
ACCURACY 
Studies have shown that the results of MRV when compared to contrast 
venography were almost similar.CEMRV has shown to be more reliable than 
venography in predicting proximal extent of DVT. CEMRV has been shown to 
have a sensitivity of 100% for iliac and femoral vein DVT with corresponding 
specificities of 100% and 97%. 
DISADVANTAGES 
There are few disadvantages that limit its utility as a screening test. One 
disadvantage is the cost which is higher than most other DVT tests. Other 
disadvantages involve patient characteristics, methodology, and safety concerns. 
Patients with certain implants may not be able to undergo testing. MRV has 
limitations related to imaging of calf veins. The paired nature of tibial veins and 
their proximity to arteries create significant artefact during post processing. 
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Methodological disadvantages include slow acquisition times and susceptibility 
to flow artefacts in parallel vessels,(common iliac  veins).CEMRV overcomes 
these disadvantages through the use of three- dimensional acquisition 
sequencing. 
Lastly, concern has been raised about the safety of gadolinium in patients with 
renal insufficiency, as there are some evidences which suggest that gadolinium is 
associated with nephrogenic systemic fibrosis. Additionally the inflammatory 
changes associated with DVT can cause gadolinium to accumulate within the 
vein wall and perivenous tissue. This characteristic enhancement pattern fades 
with thrombus organization, thus allowing differentiation between acute and 
chronic DVT. 
ADVANTAGES 
MRV complements duplex ultrasound in some cases, in that the increased ability 
to detect proximal extent of venous thrombi may advantageously affect clinical 
decision making. 
The accuracy of MRV in imaging the iliac and central venous circulation makes 
it more useful for evaluation of pelvic or central vein thrombosis. 
MRV has also shown to superior in detecting hypo gastric vein thrombosis. In 
future the ability to combine pulmonary magnetic resonance angiography and 
MRV of the lower extremities may provide a valuable diagnostic tool. 
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COMPUTED TOMOGRAPHIC VENOGRAPHY (CTV) 
This is widely used for the diagnosis of pulmonary embolism. With the 
introduction of (CTV) a single scan may become a practical a practical test for 
both DVT and pulmonary embolism. 
Studies have shown that CTV is specific but not very sensitive for the detection 
of DVT. Also CTV has not been investigated for the detection of isolated calf 
vein thrombosis. 
IMPEDENCE PLETHYSMOGRAPHY (IPG) 
IPG is based on the principle that the Impedence between two points on the skin 
of an extremity will decrease as the volume of blood contained in the extremity 
increases. IPG measures the rate of venous outflow from the calf after an inflated 
proximal blood pressure cuff is deflated, thus deducing the presence or absence 
of venous outflow obstruction. The presence of DVT in the major vessels of the 
lower extremity, including popliteal vein and proximally, should reduce the rate 
of venous outflow and subsequently affect the tracing. 
ISOTOPE SCINTIGRAPHY 
New radio pharmaceuticals have been approved for the imaging of DVT.  Tc-
apcitide is a complex of the radionuclide technetium 99m and apcitide is a small 
synthetic peptide that binds the glycoprotein 2b/3a receptor on activated platelets 
and is specific for acute thrombosis. Imaging is done 10 to 60 minutes after 
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administering the radionuclide. Venous segments above and below the knee are 
targeted. This technique has the advantage of being functional rather than 
depending on anatomical structural changes in the vein. Thus it may help in 
avoiding some problems associated with venography and ultrasonography. 
Prevention of DVT 
Primary versus secondary thrombosis prophylaxis 
Primary – given prophylactically in pre operative and early post operative 
patients. 
Secondary – after the onset of thrombosis to prevent further propagation of 
thrombus. 
As many a times the thrombosis events start primarily in operation table as it is 
shown in many studies, primary prophylaxis is gaining importance. When 
compared to olden times, the duration of stay in hospital is much shorter 
nowadays. And patients are being mobilised earlier.  
In view of all these facts the patients are being advised to continue the 
prophylaxis after discharge also. 
 Points to start post discharge prophylaxis are age older than 60 years, previous 
VTE, advanced cancer, anaesthesia lasting longer than 2 hours and bed rest for 
more than 3 days. In this group of patients it is wise to start post discharge 
comfortable prophylaxis in order to prevent DVT.  
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Evidence based versus Real clinical practice 
Over the last few years there are so many evidence based guidelines provide 
optimal DVT prophylaxis. But the clinicians at work point are not often adhering 
to these guidelines. Either over treatment for sub optimal problems or under 
treatment for florid problems is happening. Recent ACCP guidelines say that 
with adequate literature knowledge and clinical judgements, each patient should 
be viewed. The decisions should be made accordingly. In such times the patients 
risk factors for DVT, potential advantage and disadvantage of prophylaxis 
regimen has to be weighed and accordingly to be started. Local available options 
mechanical, pharmacological or combined has to be decided. 
Risk for venous thromboembolism 
It is the single most important factor to find out the risk factor in time. Timingly 
intervention prevents the evolution of risk factor to frank DVT. 
Risk for Venous Thromboembolism in Surgical Patients without 
Thromboprophylaxis 
  DVT (%) 95% CI (%) Symptomatic PE (%) 95% CI (%)
General surgery 24 23-26 1.6 1-2 
Urologic surgery 10 6-15 9 3-19 
Gynecologic surgery 16 13-19 1 0-3 
Total hip replacement 44 42-47 3 2-5 
Total knee replacement 27 22-32 —   
Hip fracture surgery 37 35-40 6 4-7 
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Risk assessment models 
Appropriate prophylaxis is to be given for individual patients according to his 
risk level. 
Low risk patient – no need for routine prophylaxis 
Moderate risk – physical methods are given with a close observation to detect 
DVT 
High risk – individualised form of prophylaxis should be given 
If the patient is diagnosed to have multiple risk factors then some form of 
prophylaxis tailored to the patient must be given. As the number of risk factors 
increases the need for prophylaxis also increases.  
ACCP guidelines do not advice prophylaxis in cases of foot and ankle surgery, 
vascular surgery, and laparoscopic procedures unless the patient has some other 
risk.  
Usually the patients are assessed by simple questionnaire listing all the risk 
factors. And the patient has to make option in the list which will be given marks 
and all the factor will be summed to give the risk. 
VTE is the leading cause of mortality in post operative patients. So measures to 
prevent it and treating it should be prioritised.  
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Like giving importance for bed sore, each patient should be given importance for 
DVT.  
Each risk factor is given highest score of 5, which indicate the incidence of DVT 
40 to 80% in this group of patients.  
In abdomen surgery done for cancer, if it is done for cancer the risk is 36%, and 
if it is done for benign indication the risk is 20% only.  
As the age increases the risk also increases. So the higher the scores are given in 
aging populations. 
Standard guideline models are ACCP guidelines, Caprini score and International 
Union of Angiology consensus statement. 
Despite these guidelines adequate prophylaxis is often not given. 
Methods of prophylaxis 
As per virchow’s triad 3 components are present. 
Hyper coagulability is common in following situations 
• post operative period 
• trauma 
• sepsis 
• cancer  
• hereditary thromphophilia 
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Likewise venous stasis is playing major role as it causes failure of clearance of 
activated coagulation factors and reduces the chance of binding with their 
inhibitors. 
Stasis also alters the laminar flow, which causes the platelets and other blood 
cells to come in contact with endothelium and adherence.  
Vascular damage, as it occurs in dilatational trauma of endothelium while 
surgery, causes the sub endothelial exposure to blood stream which causes the 
pro coagulable state. 
Methods available for DVT preventions  
Mechanical – improves venous flow and reduces the stasis 
Pharmacological – mainly acts by reducing the hypercoagulability 
Combined – often both the methods are combined for better results 
General measures 
Adequate hydration 
Adequate analgesia 
Early ambulation 
Active flexion and extension exercises if patient is bed ridden 
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Assistance of nurses and auxiliary personnel is also important to carry out 
aforementioned things. 
Leg elevation has dual effects. First it reduces the swelling thereby increase the 
venous outflow. Secondly it reduces the venous pressure by its gravitational 
effect. So it is better to be on bed with leg elevated than sitting in chair with legs 
hanging.  
Mechanical method of prophylaxis 
These have not been studied extensively. It is not given as single treatment 
modality rather given to patients to whom anti coagulants are contra indicated. 
These modalities can be either passive compression as in the case of graduated 
compression stockings (GCS) or active as in the case of intermittent pneumatic 
compression (IPC) or foot pumps. 
Apart from stasis reduction these methods also activate fibrinolytic system of 
endothelium. 
Elastic compression stockings 
They reduce the cross sectional area of veins and also increases the venous flow. 
The pressure created in this is gradient.  
At ankle level – 18 mmHg, at upper portion of thigh – 8 mmHg, is created. It 
increases the venous flow velocity up to 75%. 
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It can be either thigh length or calf length. It does not make any outcome 
difference. But calf length ECS is easy to apply, less expensive, and better 
accepted by patients. 
The incidence of DVT is reduced from 29% in control group to 15% in study 
group favouring ECS.  
For post operative patients it showed a still better response by reducing about 
69% of risk compared to control group.  
It can be used in moderate risk group patients as a single modality option.  
Limitations – lack of international standardization, physical problems like 
application, poor patient compliance, cannot be used in presence of occlusive 
arterial diseases, absent foot pulse, ABI< 0.8 
Contraindicated in massive leg edema, Congestive cardiac failure patients, 
dermatitis like conditions. 
Advantages- safe, no bleeding risk, easy to use, inexpensive, possibility to 
combine with other modalities. 
Intermittent pneumatic compression 
Its application in lower limbs is extensively studied. 
It consists of pneumatic boot or garments – wrapped around foot, electrical 
compressor to intermittently compress the foot.  
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Hemodynamic studies showed IPC enhances venous return by intermittent 
compression.  
IPC avoids venous stasis by intermittent pumping of leg veins.  
Various commonly used parameters  
• maximum pressure use 35 to 55 mmHg 
• inflation time 10 to 35 seconds 
• deflation period 1 minute 
 Device was designed to detect the functioning of this equipment to detect 
change in venous volume. 
IPC – improves venous hemodynamic, increases the fibrinolytic activity by 
increasing prostacyclin and tPA levels in blood, and it also increases the levels of 
tissue factor pathway inhibitors. 
In various studies, it is an important method of reducing the DVT in post 
operative DVT in various surgical specialities. It reduces the risk of DVT by 
about 60%.  
Of the existing prophylactic methods, IPC is the best in orthopaedic surgeries. 
When it is used in combination with warfarin, their efficacy improves to the 
highest level in orthopaedic population.  
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IPC started immediately before surgery in operation theatre and continued in post 
operative period until patient resumes normal mobility.  
As like GCS, whether to use above knee type or below knee type is still 
controversial.   
IPC is used in following conditions 
• patients at high risk of bleeding complications 
• when pharmacologic agents are contraindicated 
In one study, it is shown that up to 9% of individuals have contraindication to 
use of pharmacologic prophylaxis. In this subset, only mechanical methods can 
be used. 
Adverse effects  
• skin irritation 
• peroneal nerve palsy 
• skin pressure necrosis 
• improper sleeve placements leading to under working of machine 
Contra indications 
• Skin infections  
• Cellulitis 
• Erysipelas 
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• Massive edema – will lead to increase in preload 
• Established DVT 
• Peripheral arterial diseases 
Limitations 
• Low compliance  by Para medical persons 
• Wearing the IPC sleeves 
• Need for continuous monitoring and education of patients, attendees and nurses 
Foot compression devices 
It consists of inelastic slippers or boots with an air bladder. 
Inflation up to 200 mmHg over a period of 3 seconds period for every 20 seconds 
is used.  
So the plantar compression by this pressure causes stasis reduction and increases 
the venous outflow.  
Foot pumps reduce the incidence of DVT by about 77% compared to placebo in 
many studies.  
But is sole use in prevention of DVT in limited. So it is used when there is 
contraindication exist for pharmacologic methods present. And also in conditions 
when IPC cannot be used as the mechanical method. 
 
60 
 
Contraindications and Precautions for the Use of Anticoagulant Agents for 
the Prophylaxis of Venous Thromboembolism 
CONTRAINDICATIONS  
  •   Potential bleeding disorders 
  •   Hemophilias 
  •   Thrombocytopenia (<70,000 platelets/mm3) 
  
•   Active or recent bleeding  
  •   Esophageal varices 
  •   Active peptic ulcer 
  •   Intracranial or gastrointestinal bleeding in the past 3 months
  •   Intracranial aneurysm or angioma 
 
  •   Allergy to heparin 
  •   History of heparin-induced thrombocytopenia 
  •   Acute bacterial endocarditis 
PRECAUTIONS  
  •   Liver failure 
  •   Renal failure 
  •   Multiple trauma and head trauma 
  •   Recent intracranial, spinal, or ophthalmologic surgery
  •   Neuraxial anesthesia 
Avoid heparin, low-molecular-weight heparin, or fondaparinux injections close 
to possible surgical incisions, drains, and laparoscopic trocar sites.  
 
Pharmacologic methods of prophylaxis 
As mentioned earlier, this method counteracts, hyper coagulabity component of 
Virchow’s triad. Various components are sub cutaneous Unfractioned Heparin 
(UFH), Low Molecular Weight Heparin (LMWH), dextrans, and oral Vitamin K 
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Antagonists (VKA). More recently more promising molecules are also coming 
up.  
Unfractioned Heparin (UFH) 
It is the first method used. 5000 units were given 2 hours before surgery followed 
by 10000 to 15000 units / day subcutaneously.  
Kakkar and associates – low dose heparin significantly reduces the DVT and PE 
similar way higher doses do. 
UFH is associated with minor bleeding complications when used post 
operatively in 50 % of times. So it created a panic in those with less literature 
update. UFH reduced the DVT incidence by about 56% and PE incidence by 
30% compared to placebo. UFH is twice a day in moderate risk patients and 
thrice a day in high risk patients, subcutaneously.  
In one study, the wound hematoma rate was 3.8% to 6.2% when used in post 
operative patients.Nowadays it is mainly used in general, gynaecologic and 
urologic surgeries than any other specialities. UFH has been associated with 
Heparin Induced Thrombocytopenia in up to5% of individuals. In this condition, 
there is formation of antibodies against platelets. So it causes precipitous fall in 
platelet count, often below 10000. In 20% of patients it causes heparin related 
thrombocytopenia. UFH has a half life of about 0.5 to 2 hours. This short half 
life is taken as a advantage in renal failure.Main advantage of using this is the 
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availability of protamine sulphate, in case where there is a need for rapid 
reversal.   
Low Molecular Weight Heparin 
Its average molecular weight varies between 4000 to 8000 Daltons. These 
fractions have greater activity against factor Xa. They are able to prevent 
thrombosis without increasing bleeding risk. They have better bio availability 
and longer half life than UFH. They have low binding ability to endothelial cells, 
macrophages, and circulating proteins. So it has a predictable action than UFH. It 
is good for single daily dosing. They don’t need laboratory monitoring. It is the 
Ideal drug for outpatient monitoring. 
In one study, it shows there is no difference in their efficacy between UFH and 
LMWH, without increasing bleeding complication.  
Mismetti and colleagues analysis-  
• LMWH are better for reduction of both symptomatic and asymptomatic DVT 
compared to placebo. 
• LMWH compared to UFH also shows trend towards LMWH 
• Below 3400 anti Xa units daily showed to be effective and safe compared to 
UFH 
 Bergqvist and colleagues – higher doses of LMWH is better for cancer patients, 
because of their hyper coagulability. 
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In total hip replacement, UFH is better than LMWH. It is shown in many studies 
conducted in last 20 years. But when compared to warfarin, heparin either in toto 
or its fractions shows a better result.  
In summary, heparin either regular or fractionated by fractionation and 
depolymerisation technique is better. LMWH is the stay nowadays in both 
medical and surgical wards. Even though they are collectively called, each has 
different quality and actions. So should not be given in exchange.  
Oral Vitamin K Antagonists 
Coumarin derivatives are the agents that are commonly used. Synthesis of active 
clotting factors II, VII, IX and X needs carboxylation of glutamic acid residues. 
Warfarin is the most commonly used drug .It is administered orally. Dosage – in 
fixed dose it does not need laboratory monitoring as they are well studied before. 
In adjusted doses it is necessary to monitor the treatment regularly. For 
monitoring purpose PT and INR are being used. In high risk patients INR to be 
maintained between 2 and 3.Most of these drugs need 3 to 4 days to reach the 
therapeutic plasma concentration. So on the evening of surgery these drugs are 
started, so that the required concentration comes around 4th post operative day. 
Advantages – oral administration,  
Disadvantages – risk of bleeding, laboratory monitoring, drug interactions, diet 
related absorption changes. The effect can be neutralised with Vitamin K, 
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Prothrombin concentrates and fresh frozen plasma. Even then they are inferior to 
LMWH. But it is commonly used by orthopaedic surgeons for prophylaxis.  
Aspirin  
Aspirin irreversibly inhibits cyclooxygenase – 1 enzyme and further production 
of thromboxane A2.Due to its irreversible action, the action lasts for about 7 -10 
days , the platelet half life. It is mostly used in arterial conditions requiring 
anticoagulation. They don’t have any difference between low and high doses 
either in anticoagulation or bleeding risk. But it is often inferior to other methods 
like Heparin.In hip fracture and total hip replacement, aspirin is found to be 
better than other methods. 
New Antithrombotic Anticoagulants 
Limitations with currently available anti coagulants  
• Insufficient efficacy in special situations 
• Subcutaneous administration 
• Risk of thrombocytopenia 
• Need for laboratory monitoring 
• Narrow therapeutic margins 
So, in order to overcome all these, major effects are being taken to develop drugs 
that will inhibit single enzyme and avoiding all the complications. Subsequently 
these drugs will replace UFN and LMWH. 
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Factor Xa Inhibitors (Indirect: Fondaparinux and Idraparinux) 
Fondaparinux 
A synthetic pentasaacharide. Inhibits factor Xa by making conformational 
change in Antithrombin molecule. High bio availability.Subcutaneous 
injection.17 hours half life.It does not cause thrombocytopenia and 
osteoporosis.It should be started 6 to 8 hours after the end of surgery. As long as 
the drug is continued there is substantial reduction of DVT risk, as shown in 7 
and 30 days DVT incidence studies.  
FDA has approved for the following indications 
• Total hip replacement 
• Total knee replacement 
• Hip fracture surgery 
PEGASUS study – high risk abdominal surgery 
• 2.5 mg post operatively studied versus dalteparin 
• No difference of bleeding complications 
Idraparinux  
130 hours half life.Once a week administration 
Disadvantage – long half life without antidote 
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Direct Factor Xa inhibitors – Rivaroxiban 
Direct selective reversible inhibitor of factor Xa.Oral drug.Absorbed 
rapidly.Maximum plasma concentration after 2 to 4 hours.Half life between 5 
and 9 hours.Initial dose given 6 to 8 hours after surgery.Acceptable safety limits 
and no need for laboratory monitoring.10 mg daily is now accepted as standard 
dose.Yet much result about the drug is awaited. 
Direct Thrombin Inhibitors (DTI) 
Normally thrombin converts fibrinogen to fibrin. Activates factor V, VIII, and 
XI. Stimulates platelets, stabilises fibrin by activating XIII. It directly binds to its 
catalytic site. Heparin inhibits only the free thrombin. But clot bound thrombin 
causes further propagation of thrombus.On the contrary, DTI’s inhibit both free 
and clot bound thrombin. They do not bind with plasma proteins and will not 
interact with platelet factor. It will not cause thrombocytopenia. 
Hirudin 
Leeches saliva derivative. First DTI used. Desirudin is a recombinant product of 
Hirudin. Subcutaneous injection. Mainly used for hip arthroplasty post operative 
patients to prevent VTE.Bleeding complication is high with this drug.Hirudin 
and argatroban, a new DTI, have got approval for Heparin Induced 
Thrombocytopenia (HIT) 
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Dabigatran Etexilate 
Orally administered DTI. High affinity and specificity for thrombin. Peak plasma 
concentration occurs in 2 hours. Half life after single dose is 8 to 10 hours. But 
after 14 to 17 hours, it increases up to 14 to 17 hours. Usually started after 1 to 4 
hours after the end of surgery.Advantages – orally administered, no need for 
routine monitoring, fixed doe regimens are possible.Combination of mechanical 
and Pharmacological methods 
As the result of combining both mechanical and pharmacological methods, two 
of three risk factors of Virchow’s triad are being addressed.Both are 
complementary to each other not antagonist.Combining stockings of any type or 
IPC with either heparin or others results in better outcomes and protection.  
In Cochrane collaboration review, it is shown about 80% increased reduction 
achievement when combined modalities are being used. 
Apollo study – IPC and Fondaparinux vs Fontaparinux alone – results showed 
combined modality is better option than either of these alone. 
Recommendations for Prophylaxis of Venous Thromboembolism in Surgical 
patients. 
The type and duration of surgery and presence of risk factors only ultimately 
decide the need.In patients of low risk – early ambulation and observation – no 
need for pharmacological prophylaxis.In moderate risk patients – UFH 5000 
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units twice daily, LMWH < 3400 units once a day- some groups say only 
mechanical methods. In high risk patients – active cancer, previous VTE, 
multiple risk factors – combined modality treatment. Duration of prophylaxis – 
usually until discharge. For abdomen cancer surgery – LMWH for 3 to 4 weeks. 
If the patient has active bleeding or high risk for bleeding complication – 
mechanical methods should be used. Once the complication settles then it is 
changed to pharmacologic method.  
Agent Dose Initial dose 
Unfractionated 
heparin 5000 U every 8-12 hr 1-2 hr before surgery 
Vitamin K 
antagonists 
5-10 mg (warfarin) (INR of 
2.5) 
Day of surgery or 1st postoperative 
day 
Fondaparinux 2.5 mg 6 hr after end of surgery 
Low-molecular-weight heparins 
Moderate risk      
Dalteparin    2500 U daily 1-2 hr before surgery 
Enoxaparin    20 mg (2000 U) daily 1-2 hr before surgery 
Nadroparin    2850 U daily 2-4 hr before surgery 
Tinzaparin    3500 U daily 2 hr before surgery 
Bemiparin    2500 U daily 2 hr before or 6 hr after surgery 
High or highest risk    
Dalteparin    5000 U daily 8-12 hr before surgery 
Enoxaparin   40 mg (4000 U) daily 10-12 hr before surgery 
Nadroparin   ≥3800 U daily 2-4 hr before surgery 
Tinzaparin    50 U/kg daily 2 hr before surgery 
Bemiparin    3500 U daily 2 hr before or 6 hr after surgery 
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Risk Level Prophylaxis Regimen 
Low riskEarly and aggressive mobilization 
Moderate 
risk LMWH at low doses (<3400 U daily) 
  Unfractionated heparin (5000 U twice daily) 
  
Elastic stockings (18-23 mm Hg) or IPC, especially in patients in whom 
anticoagulants are contraindicated 
High riskHigh-dose LMWH (>3400 U daily) 
  Unfractionated heparin (5000 U every 8 hours) 
  
Elastic stockings (18-23 mm Hg) or IPC, especially in patients in whom 
anticoagulants are contraindicated 
  Combination of high-dose heparin or LMWH with stockings or IPC 
Highest 
risk High-dose LMWH (>3400 U daily) 
  Unfractionated heparin (5000 U every 8 hours) 
  
Elastic stockings (18-23 mm Hg at the ankle) or IPC, especially in 
patients in whom anticoagulants are contraindicated 
  Combination of high-dose heparin or LMWH with stockings or IPC 
  
Warfarin for patients undergoing hip or knee arthroplasty (target INR of 
2-3) 
  Fondaparinux (2.5 mg daily) 
  
In patients undergoing major orthopedic or abdominal cancer surgery, 
consider extending prophylaxis with LMWH for 28-35 days 
 
Timing of prophylaxis 
1 or 12 hours before surgery. In one study fondaparinux and dalteparin 
compared, no advantage of either drug in 6 or 8 hours after the end of surgery 
has been concluded. 
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Vascular surgery 
Patients undergoing vascular surgeries receive several antithrombotic agents, anti 
platelets and anti coagulants. So the incidence of DVT is low. Risk factors in 
these patients are advanced age, limb ischemia, long duration of surgery, and 
intra operative local trauma including venous trauma. Latest consensus says that 
no special prophylaxis is needed in addition to all those. Based on individual risk 
factors only type of prophylaxis, duration and starting time are to be started. 
Multiple trauma 
 Spinal injuries are associated with highest incidence of VTE and PE. PE is the 
third leading cause of death. All trauma patients should receive either physical or 
pharmacological method of prophylaxis. The greatest risk is present in the first 
three months. Routine duplex scan is advised. IVC filters role is still 
controversial.  
Laparoscopic surgery 
Theoretically it is a less thrombogenic surgery. Reasons – less tissue trauma, 
early ambulation.  
But in surgeries like cholecystectomy and hiatal hernia – reverse Trendelenberg 
position, 12 – 14 mmHg pneumoperitoneum – impaired venous return, venous 
stasis. 
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In laparoscopic cholecystectomy, the incidence of symptomatic DVT, PE, and 
fatal PE are 0.02%, 0.03% and 0.02%.  
A recent prospective study revealed 16% of DVT incidence in OC compared to 
7% incidence of DVT in LC. 
The recommendations of Society of American Gastrointestinal and Endoscopic 
Surgeons are given in the following guidelines.  
Procedure Risk factors Recommendation 
Laparoscopic cholecystectomy 0 or 1 None, IPC, LMWH, or UFH 
  ≥2 IPC, LMWH, or UFH 
Laparoscopic appendectomy 0 or 1 None, IPC, LMWH, or UFH 
  ≥2 IPC, LMWH, or UFH 
Laparoscopic Nissen procedure 0 or 1≥2 IPC, LMWH, or UFHIPC and UFH or LMWH 
Laparoscopic splenectomy 0 or 1≥2 IPC, LMWH, or UFHIPC and UFH or LMWH 
Other major procedures 0 or more IPC and UFH or LMWH 
 
Bariatric surgery 
Patients with >30kg/m2 BMI are at increased risk of DVT.  
In one mayo clinic study, about 50% of all fatal PE occurred in obese. 
All obese patients should receive prophylaxis. 
Doses of drugs also need to be increased about 25%. 
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Patients with 35 to 40 kg/ m2 BMI are at increased risk of prolonged surgery and 
restricted post operative mobility. 
0.1 To 2% of bariatric surgery patients who received prophylaxis also developed 
VTE. 
Risk factor in bariatric surgery patients  
• severe chronic venous insufficiency of legs 
• BMI greater than 60kg/m2 
• Abdominal obesity 
• Sleep apnoea syndrome 
• History of DVT 
• Smoking 
• Anastomotic leak 
• >50 years of age 
 Recommended prophylactic methods 
• Heparin SC at 5000 to 7500 units every 8 hours 
• Intravenous infusion at 400 U/Hr 
• Heparin dose adjusted to plasma anti Xa activity between 0.11 and 0.25 U/hr. 
• Enoxaparin 40 to 80 mg/ day 
• Nadroparin 5700 to 9500 U/day 
• Dalteparin 5000 U/day 
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Mechanical methods are not used as the sole method. When used with 
pharmacologic methods it definitely augments other methods and reduces the 
incidence of DVT. It is shown in many studies. 
Duration of prophylaxis is not yet concluded. Studies are still on these areas. 
Cancer surgery 
Normally this group of patients have a fourfold risk of VTE.  
When chemotherapy is instituted it further increases the risk.  
In addition these patients are at increased risk of recurrence. 
The rate of VTE is high in cancers of lung, pancreas, colon, stomach, kidney and 
prostate. . 
When these cancer patients undergo surgery, the risk further increases twofold in 
post operative period. 
In one study DVT incidence in general surgery, with cancer patients was about 
37% and 20% without cancer. 
In cancer patients, there is platelet activation and aggregation and 
hypercoagulability secondary to procoagulant released by tumours as well as 
increased release of tissue factors.  
In addition vessel wall damage during radical surgeries, central lines, 
chemotherapy and radiotherapy causes further risk. 
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Vessel compression by tumours causes venous stasis also in these patients.   
The patients undergoing these surgeries should be given 5000 units, 8 hourly 
regularly. 
Due to hypercoagulable states these patients are given higher doses of drugs to 
compensate it. 
The recommended LMWH are 40 mg of enoxaparin and 5000 units of dalteparin. 
For other LMWHs, >3400 units daily are to be given. 
In abdomen surgeries fondaparinux 2.5mg daily is recommended.  
Regular duration of prophylaxis is at least 7 days. But for 4-5 weeks is given in 
abdomino pelvic cancer surgery, residual malignancy patients, obesity and 
history of DVT. 
20 to 25% of all patients with symptomatic VTE have cancer in some form. 
Orthopaedic surgery 
Total hip/knee replacement surgeries and fractured hip definitely need 
prophylaxis. 
VKAs are most commonly used. Because it is taken orally and associated with 
less post operative bleeding. 
Fondaparinux has shown the best venographic clearance rate compared to other 
drugs with no bleeding complication risk. 
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Prophylaxis in spinal surgery is not well studied, as this group of patients 
routinely given prophylaxis.  
Neurosurgery 
These are the patients at very high risk of bleeding, as they cannot be given 
pharmacologic prophylaxis, because of catastrophic bleeding risk. All these 
patients are given routine IPC or GCS along with UFH or LMWH appropriately. 
Inferior vena cava filters are also tried with varied success rates. 
Timing and duration of prophylaxis 
Timing  
Fibrinogen scan data – about half of DVT, process starts in operating table itself. 
Death from fatal PE is reduced by 50% in last 30 years, as shown in many 
studies. In these studies, anticoagulants were given 2 hours pre operatively and 
they were also associated with less bleeding rates. In one recent study, 
eliminating the pre operative dose reduced the bleeding complications and 
associated with no change in efficacy. 
Duration - One recent study showed 40% of DVT is occurring in more than 21 
days after surgery. So it is necessary to extend the period of prophylaxis till this 
period of risk. 
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In one study comparing 7 days versus 30 days LMWH, showed that 30 days 
heparin is associated with less incidence of DVT. Individual patient should be 
considered for duration deciding.Bleeding complications in surgical patients 
receiving anticoagulants6% of general surgical patients developed post operative 
bleeding after prophylaxis with UFH.  Similarly 2.8% of major haemorrhage and 
3.8% wound hematoma are associated with LMWH prophylaxis.0.2% of GI 
bleeding and 0.1% of retro peritoneal bleeding were reported.  In major 
orthopaedic injury 2% of times major bleeding is associated. The timing of 
administration is a important deciding factor in orthopaedic surgeries. The 
current recommendation is to wait 8 – 12 hours post operatively for initiating 
LMWH and 6 hours minimum for fondaparinux.  
Neuraxial anaesthesia in prophylaxis patients 
American Society of Regional Anaesthesia  
• Regional anaesthesia avoided to the possible extent 
• Minimum time gap between LMWH to spinal injection should be 10 to 12 hours 
• If hemorrhagic aspirate is present initially, then procedure should be abandoned 
• Single shot spinal is advised than epidural 
• Minimum of 2 hours should be allowed from LMWH to spinal needle placement 
All these patients are given some form of mechanical prophylaxis. 
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Physician attitudes and practices 
Recently published data showed that only 55% of physicians are adhering to the 
guidelines for treatment. 
They use LMWH lesser time than expected. 
Lacking areas are inadequate dosage, inadequate bridging of heparin to warfarin 
and failure to give post operative prophylaxis. 
Ultimately the already treated patients are 50% of times are at risk of developing 
thrombosis subsequently. 
Hospitals should have individual policy for these regimens and adherence should 
be evaluated periodically. 
Prophylaxis for medical patients 
50 to 75% of all cases occur in medical background than surgical back ground. 
GCS alone or 5000 units of UFH, twice daily was the reason for all these 
failures. 
Anticoagulant prophylaxis reduced the incidence of clinical and fatal PE. Both 
UFH and LMWH are used in these patients. But co morbid should be considered 
before giving these drugs. 
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Treatment 
Objectives – prevent thrombus extension, early recurrence, and death from PE. 
Also to prevent late recurrence and PTS and chronic pulmonary hypertension. 
Mobilisation and Leg elevation 
Early ambulation should be done. This causes pain and swelling to come down 
early. Compression stocking are to be done at the earliest.   
Anticoagulation 
As soon as to be started. High clinical suspicion or objective evidence is needed. 
Either IV or SC UFH or LMWH is to be given along with VKA. This overlap for 
about 5-10 days is necessary, with discontinuing the UFH or LMWH after the 
INR reaching 2 to 3 for two consecutive days. 
aPTT (sec) Heparin Dose 
Initial dose 80-U/kg bolus, then 18-U/kg/hr IV infusion 
<35 80-U/kg bolus, then increase 4-U/kg/hr infusion 
35-45 40-U/kg bolus, then increase 2-U/kg/hr infusion 
46-70 No change (corresponds to 0.3-0.7 anti-Xa U/mL) 
71-90 Decrease infusion rate by 2 U/kg/hr 
>90 Stop infusion for 1 hour, then decrease infusion by 3 U/kg/hr 
 
 Unfractionated Heparin 
IV regimen – 80 IU/kg bolus followed by 18IU/kg/hr continuous infusion. The 
aPTT is done 6 hours after first bolus dose and titrated accordingly. 
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SC regimen – 5000 units SC, followed by 17500 IU twice daily to achieve the 
aPTT of 1.5 to 2.5. 
Low Molecular Weight Heparins 
100 anti Xa U/kg every 12 hours or 150 anti Xa U/kg every 24 hours for 
enoxaparin. 100 anti Xa U/kg twice daily or 200 anti Xa U/kg every 24 hours for 
dalteparin. 175 anti Xa U/kg every 24 hours for tinzaparin. 
Fondaparinux  
Subcutaneous injection, once daily, 5, 7.5, 10 mg OD, according to INR 
Thrombolysis 
It is indicated for painful, swollen limb, skin changes, ulceration and functional 
disability. Catheter directed therapy is best. Access is via popliteal vein. Also we 
can stent the area in case of anatomic abnormality.  
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ACUTE DEEP VENOUS THROMBOSIS: SURGICAL AND 
INTERVENTIONAL TREATMENT 
Acute DVT represents a disease spectrum which ranges from asymptomatic calf 
vein thrombosis to PHLEGMASIA CERULEA DOLENS. Till recent times, 
guidelines only recommended anti coagulation. However 8th ACCP conference 
suggests interventional strategies may be developed to reduce PTS. 
UNDERSTANDING POST THROMBOTIC VENOUS INSUFFICIENCY 
Recent ACCP guidelines recommend major differences from earlier guidelines. 
Extensive venous thrombosis supports use of venous thrombectomy grade 2b and 
catheter directed thrombolysis grade 2b, thrombolytic therapy used when these 
techniques are not available. Thrombolysis is most effective when plasminogen 
activator is delivered directly into the thrombus. Pharmacological techniques 
have found to reduce treatment time and dose of plasminogen activator 
MORBIDITY OF PTS 
Early elimination of thrombus prevents morbidity. There is significant reduction 
in quality of life which is predicted by the severity of the disease. In ilio-femoral 
DVT treated by anti-coagulation alone, 90% have ambulatory venous 
hypertension, 40% venous claudication, 15% venous ulceration within 5 years. 
This shows that thrombus removal is the best management for best long term 
outcome 
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RATIONALE OF THROMBUS REMOVAL 
Ambulatory venous hypertension is the cause of microcirculatory changes which 
is the Pathophysiology of PTS. There is venous valvular incompetence and 
luminal obstruction. No single radiological technique exists to assess the impact 
of venous obstruction on severity of PTS. Neither ascending phlebography nor 
maximal venous outflow test can identify abnormalities causing venous 
obstruction. Luminal venous obstruction causes severe forms of venous 
obstruction. Thus early detection and intervention in acute stage significantly 
reduces incidence of PTS. Acute successful thrombolysis preserves endothelial 
function and valvular competence 
STRATEGIES FOR THROMBUS REMOVAL 
Poor randomised trials and lack of international guidelines coupled with age old 
data are major roadblocks. CDT benefit has been enunciated recently. In the 
absence of large randomised trials clinical data is to be trusted which suggests 
CDT is superior to anticoagulation 
CURRENT ACCP GUIDELINES  
Current guidelines recommend operative venous thrombectomy to be preferred 
in low risk of bleeding and contemporary venous thrombectomy when CDT is 
indisposed of. Anti coagulation therapy of same intensity and duration is to be 
coupled for better outcome. 
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TREATMENT OPTIONS FOR THROMBUS REMOVAL 
CDT is the preferred treatment to store unobstructed venous return to the vena 
cava. Preoperative knowledge and intra operative imaging of extent of thrombus 
is crucial for success. 
THROMBOLYTIC THERAPY 
Anticoagulation therapy was initially systemic and insufficient for clearing 
thrombus to return venous patency and valve function. Initial lytic therapy had 
significant venous valve competency but benefits were not as apparent and 
bleeding tendencies were more 
INTRA THROMBUS CDT 
Pathophysiology of thrombus includes creating binding sites for plasminogen 
activators and production of plasmin. Thus intra thrombotic delivery of 
plasminogen activators is better than systemic. Bleeding disorders is a rarity 
localised to venous access site. Pulse spray technique of four sessions had 50-
70% lysis and little bleeding manifestations. There was continued lysis after 
treatment sessions 
OUTCOMES  
CDT was associated with better QOL than anticoagulation alone. But large 
randomised studies are required. Two such studies are underway 
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PHARMACO-MECHANICAL THROMBOLYSIS 
CDT provides good results but at the cost of longer duration approximately 71 
hours. Endovascular mechanical thrombectomy 
ENDOVASCULAR MECHANICAL THROMBECTOMY 
Mechanical thrombectomy was found to be less effective than when combined 
with pharmacological thrombolysis by Vedhantham and associates and Kasirajan 
and associates. 
ULTRASOUND ACCELERATED THROMBOLYSIS 
Treatment time and dosage of lytic agent was found to be less with ultrasound 
accelerated thrombolysis with an infusion time of 22 hours and only 4 % people 
suffering major complications such as puncture site hematomas 
ISOLATED SEGMENTAL PHARMACO-MECHANICAL 
THROMBOLYSIS  
This is done using Trellis catheter. A double balloon catheter is inserted into the 
thrombus and one balloon is inflated above the level of the thrombus while the 
other is inflated below the level of the thrombus trapping the thrombus within. 
Plasminogen activator is released into the thrombus. The intervening segment of 
the catheter assumes a spiral configuration and rotates at the rate of 1500 rpm for 
15-20 minutes. The thrombus is fragmented and dissolved within and is 
aspirated. Phlebography demonstrates the success of the procedure. ISPBT was 
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found to have better success rate than CDT alone but the bleeding complications 
were equivocal 
OPERATIVE VENOUS THROMBECTOMY 
This offers by far the best short term and long term outcomes with comparatively 
few complications. But this depends upon technical skill and prevention of 
recurrent thrombosis 
It involves identification of cause, definition of full extent, preventing pulmonary 
embolism, thrombectomy, to ensure unobstructed venous inflow and outflow and 
preventing recurrent thrombosis by AV fistula, extended oral anti coagulation, 
catheter directed post operative anti coagulation 
PREOPERATIVE CARE 
This involves use of unfractionated heparin, identification of full extent of 
thrombus and vena caval filtering. It is done under fluoroscopic guidance and the 
entire pelvic and abdominal venous system should be in the field 
OPERATIVE CARE 
General anaesthesia is recommended for these patients. Longitudinal venotomy 
is made in the common femoral vein ensuring access to the origin of the 
saphenous and profunda femoris branches. In case of an infra inguinal thrombus 
leg is elevated and compressed with a tight bandage and the foot dorsiflexed, calf 
and thigh are squeezed. If the infra inguinal thrombus persists a curt down has to 
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be performed to expose the distal posterior tibial vein and a No 3Fogaty catheter 
is introduced and advanced up to the common femoral venotomy. The silastic 
stem is amputated from its hub and inserted half way onto the balloon catheter 
and out of the common femoral venotomy. Now a NO 4 Fogarty balloon catheter 
is placed at the other end of the silastic sheath and guided distally through the 
thrombosed valves and clotted veins up to the posterior tibial venotomy. The 
infrainguinal venous thrombectomy is performed. The infrainguinal venous 
system is flushed with a large red rubber catheter in the proximal posterior tibial 
vein with a heparin saline solution to hydraulically force residual thrombus from 
the deep venous system. After adequate clearance of infrainguinal venous 
system, vascular clamp is applied below the femoral venotomy and dilute 
plasminogen activator solution consisting of 4-6 mg of rtPA in 200 ml of saline 
is filled in the infrainguinal venous system. The plasminogen activator solution 
remains there for the rest of the procedure. The local rtPA binds to fibrin bound 
plasminogen in residual thrombus and promotes further clot dissolution while not 
causing a systemic lytic response. If the infrainguinal venous thrombectomy is 
not successful the femoral vein is ligated and divided below the profunda 
femoris. Iliofemoral venous thrombectomy is now performed with a No 8 or 10 
venous thrombectomy balloon catheter. It is passed partially into the iliac vein to 
remove the bulk of the thrombus before advancing the catheter into the vena 
cava. The proximal thrombectomy is performed under fluoroscopic guidance. 
During this part of the procedure PEEP is given to reduce the risk of pulmonary 
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embolism. If a clot is present in the vena cava caval thrombectomy can be 
performed as an alternative to vena caval filtration. The nature of the venous 
drainage into the vena cava is assessed using intraoperative phlebography or 
fluoroscopy. Intravascular ultrasound is better for detecting iliac vein stenosis. 
Once the venotomy is closed and end to side AV fistula is constructed to increase 
venous velocity but not pressure. A piece of polytetrafluroethylene or silastic is 
kept around the saphenous AVF and permanent monofilament suture looped to 
serve as a guide for future dissection. Closed suction drain is placed in the wound 
to evacuate any sero-sanguinous fluid that accumulates post operatively and the 
wound is closed with multilayered running absorbable sutures for better 
haemostatic and lymphostatic wound closure and elimination of dead space. 
Paediatric feeding tube is inserted and fixed to the proximal posterior tibial vein 
for post operative anticoagulation while the distal posterior tibial vein is ligated.  
POSTOPERATIVE CARE 
Therapeutic anticoagulation with UFH through posterior tibial vein catheter is 
given. Before removal of the catheter an ascending phlebogram is done. 
Intermittent pneumatic compression garments are used when the patient is not 
ambulatory. 30-40 mm Hg ankle grading below knee compression stockings can 
also be used with the benefit of 50% reduction in post thrombotic morbidity. 
Venous duplex and other venous duplex function studies are performed for 
evaluating vein valve function and ultrasonic patency. 
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 RISK ASSESSMENT. Patients at highest risk for procedure related PE are the 
ones with non obstructive venous thrombus.  Systemic complications are reduced 
with modern techniques such as direct intrathrombus infusion, pharmaco 
mechanical techniques, etc. reduction in the dose of lytic agent, duration of 
therapy, circulating antiplasmins and Plasminogen activator inhibitors serve to 
neutralise the systemic effect of lytic therapy. 
PRE TREATMENT EVALUATION 
Etiological factors such as trauma, underlying thrombophilia, occult cancer etc 
have to be evaluated before choosing the treatment options.  
IMPORTANCE OF IMAGING 
Imaging of the vena cava is important to assess the degree of venacaval 
involvement. Characterisation of the proximal and distal end of the thrombus is 
very important. A CT of chest, abdomen and pelvis is an important part where an 
asymptomatic PE may be found. This helps distinguish pre-treatment PE from 
treatment failure/complication of lytic therapy or venous thrombectomy.  
INTERVENTIONAL TREATMENT OF PE 
Most cases of acute PE anticoagulation alone are sufficient. However large PE 
causing hemodynamic instability and/or PHT require restoration of normal 
outflow from RV thereby avoiding chronic thromboembolic PHT. Systemic 
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thrombolytic therapy includes RV and pulmonary function decrease chronic PHT 
and recurrent venous thromboembolism. 
When contraindicated, catheter based techniques can be used. Modified rotating 
pigtailed catheter is used as a part of catheter based thrombolysis. 13mg of rtPA 
is injected after embolic disruption and manual clot aspiration done.  
Rheolytic thrombectomy combined with infusion of plasminogen activator 
solution seems to be a better technique.  
PATIENT EVALUATION 
All patients with PE should be evaluated with cardiac ECHO to assess 
pulmonary artery pressure and RV function. Significant morbidities which is 
right heart abnormalities- RV dilatation, Tricuspid insufficiency and PHT 
warrant catheter based fragmentation with thrombolysis or systemic 
thrombolysis.  
VENA CAVAL INTERRUPTION  
       PE is the significant cause of mortality. It is managed with anticoagulants 
which decrease recurrence and risk of bleeding complications.  
When this anticoagulation fails or is contraindicated, vena caval interruption with 
a filter device is appropriate.  Initially femoral vein ligation, IVC ligation & 
partial interruption of IVC were used. But these turned out less effective in 
preventing the problems. Following this technique of Trans venous delivery of 
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intra vascular vena caval devices. At first these filters were fitted in the operation 
room but now it is placed bedside under transabdominal or intravascular 
ultrasound guidance. 
 FILTER DESIGN 
The filters are designed with the aim of trapping the venous thromboembolism in 
the vena cava. The material used should be non thrombogenic, biocompatible, 
non Ferro magnetic, durable & implantable. 
 IVC FILTERS 
Considering the anatomy of inferior vena cava and a note on the variations 
before filter placement. 
     The variations include IVC transposition, duplication, IVC agenesis, renal 
vein anomalies.  
1. IVC TRANSPOSITION:  
  Generally the left sided IVC drains into left renal vein, crosses to right and 
continues in cephalic direction. Filters can be placed but the location of renal 
veins should be accurately defined& suprarenal vena cava placement may be 
preferred. 
2. IVC DUPLICATION: 
 It is present in 0.2-0.3%. The right iliac and right renal vein typically drains into 
right IVC whereas the left sided IVC drains left iliac vein, joins the left renal 
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vein, where it crosses over into the right sided vena cava. Thus with this 
anomaly, placing a filter in the right IVC may not adequately prevent PE in a 
patient with left sided DVT.  In this case, placing a filter in each vena cava or in 
the suprarenal vein after crossing the left renal vein is required. 
3. RENAL VEIN ANOMALIES: 
The common anomalies are retro or circumaortic left renal vein or multiple 
bilateral renal veins.  Of these the circumaortic renal veins have separate 
drainage, so the tip of the filter is positioned inferior to the lowest portion of the 
circumaortic vein 
4.  IVC AGENESIS: 
There can be abnormal IVC with azygos drainage or infrahepatic interruption of 
IVC with azygos continuation.  
TECHNICAL CONSIDERATIONS 
         To place the filters with accurate assessment of venous anatomical 
landmarks &under fluoroscopic guidance VENOGRAPHY is the best technique 
used. Still complications such as hematoma formation, arterial puncture, air 
embolism, malpositioning, pneumothorax & AV fistulas occur.  Bird’s nest filter 
has a higher mortality rate compared to other filters probably patient’s co 
morbidity adding to it. A thrombus in the IVC or a malpositioned infrarenal 
filter, or duplicate IVC necessitates the placement of a SUPRARENAL FILTER. 
            To prevent the complications during the transport of the patient for filter 
placement, bedside placement under transabdominal duplex ultrasound or 
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intravascular ultrasound guidance and it is even cost effective. If the 
transabdominal ultrasound cannot image adequately bedside intravascular 
ultrasound was performed. The major risk with bedside insertion is 
malpositioned filters. It can be managed by repositioning or insertion of a second 
filter or percutaneous retrieval is possible. Bedside filter techniques have more 
advantages than contrast enhanced venography. 
VENOGRAPHY GUIDED FILTER PLACEMENT 
     On the basis of filter type and the clinical situation access can be femoral, 
jugular or antecubital. The fluoroscopy can either be in a operating room setting 
with C arm fluoroscope or in endovascular or radiological suite with fixed arm 
imaging. Guide wire and catheter access is useful in initial non selective 
venography. The images are obtained to confirm landmarks, correlate bony 
landmarks, presence of thrombus at the filter placement level. This correlation 
has lead to the study of different positions of the renal vein in relation to lumbar 
vertebra and disc spaces. It corresponded to L1 in 17.3%, L1 L2 disc space in 
36.5%, L2 in 34.6%, L2L3 disc space in 7.7%.Similarly in common iliac vein. 
For a suprarenal filter placement, venographic imaging of the suprarenal vena 
cava is needed to confirm the level of renal veins. Normally the suprarenal vena 
cava is larger than the IVC. Thus accurate diameter measurements should be 
made to confirm the diameter. The filter leg attachment point should be above 
the most cephalic renal vein else the filter may tilt.  
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TRANSABDOMINAL DUPLEX ULTRASOUND GUIDED FILTER 
PLACEMENT 
 It is done to assess if the visualization of IVC at the renal vein level is adequate 
in both transverse and longitudinal axis. The lowermost renal vein that is the 
right renal vein is to be identified with the help of the right renal artery. A venous 
access is obtained and a guide wire is passed under Duplex ultrasound 
visualization. After visualizing the right renal vein- IVC junction, filter delivery 
catheter is advanced inside to the renal vein level. Ensuring its correct position, 
the sheath ids pulled back slowly such that the filter delivery catheter tip is at the 
renal vein level. With direct visualization under duplex ultrasound the filter is 
deployed. Post deployment duplex imaging ensures proper position of the filter 
in IVC. 
INTRAVASCULAR ULTRASOUND GUIDED FILTER PLACEMENT. 
 A percutaneous femoral vein access is obtained under local anaesthesia. The 
intravascular ultrasound probe is inserted into the sheath and directed up to the 
level of right atrium of the heart. The venous anatomical landmarks such as right 
atrium, hepatic vein, renal vein, & confluence of the iliac vein are identified by 
pull back technique. The ultrasound probe is directed just below the level of the 
lower most renal vein and the IVC diameter is recorded before proceeding with 
deployment of filter. The filter delivery is advanced to the mark in case of 
predetermined marks by aligning the tip of the filter with the end of the sheath. 
In case of systems without predetermined marks, the sheath is first pulled to a 
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distance equivalent to the filter delivery catheter extends beyond the sheath. This 
enables the tip of the filter to align with the lowermost renal vein on deployment. 
When a single venous access is not possible, dual venous access is adapted. 
Separate venous access in contralateral femoral vein, thus avoids double large 
sheaths in the same femoral vein. Ipsilateral femoral vein probe is used in case of 
contralateral venous thrombosis. The filter is deployed through pull back 
technique. To confirm the filter position post procedure plain X RAY Abdomen 
are taken. 
FILTER RETRIEVAL 
A retrieval time period is to be determined when the risk of PE is low, or when 
anticoagulation can be restarted. Ensure radio graphically that there are no filter 
related problems which hinder their retrieval. Detect the presence of any 
thrombus within the filter using venography in which case filter is left in place. 
On the basis of filter types different approaches and techniques are used. If there 
is difficulty in releasing the filter from the IVC attachment, retrieval is aborted. 
For the “difficult to remove filters” or malpositioned filters, special techniques 
such as bronchoscopic forceps can be used. 
SVC FILTERS 
The most important causes for upper extremity DVT is the use of central venous 
access, thoracic outlet related venous occlusion, implantable defibrillators, 
sepsis, malignancy, thrombophilia. When anticoagulants are contraindicated 
superior vena cava filter is used for upper extremity DVT. Percutaneous Jugular 
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or femoral venous access is obtained. If the situation arises where the superior 
and inferior vena cava are to be placed simultaneously, the most distal filter is to 
be placed first. Remove any previous central venous catheters. Superior vena 
cava anatomy is studied detail under venography and any anomalies must be 
appreciated. Venography also determines the filter leg attachment which is just at 
the confluence of innominate veins. The filter leg length should be determined in 
such a way that it does not enter into the right atrium. With correct position and 
size the filter is passed through the sheath and the filter is deployed. 
Complications such as filter malpositioning, superior vena cava perforation, 
pneumothorax, and guide wire entrapment, erosion into thoracic aorta. 
SPECIFIC PATIENT GROUPS 
TRAUMA PATIENTS 
The risk of developing DVT and PE is as high as 50% & 30%. The risk factors 
include advancing age, multiple transfusions, high injury severity score, head 
injury, spinal cord or vertebral injury, long bone fracture, multiple transfusions. 
Contributing to this are prolonged immobility, venous stasis & proinflammatory 
hypercoagulable state. Thromboprophylaxis is preferred for trauma patients with 
at least one risk factor. Mechanical thromboprophylaxis is preferred in patients 
who cannot receive anticoagulants. Trauma patients at high risk are suggested 
routine prophylactic filter placement. Use of retrievable filters in the high risk 
trauma patients has repoted success. Use of IVC filters is indicated in patients 
with proven DVT and a contraindication to therapeutic coagulation. 
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BARIATRIC PATIENTS 
        Obesity poses a strong risk for developing venous thromboembolism. The 
most common cause of Perioperative death in bariatric patients is PE.The 
mortality is due to improper dosing of the anticoagulation thromboprophylaxis 
the anticoagulation has many drawbacks even with standard heparin protocols. 
Thus vena cava filter placements have become increasingly common.  Several 
indications such as BMI >60, hypoventilation syndrome, truncal obesity were 
considered for prophylactic filter placement.  The optional / retrievable filters are 
used in the highest risk period following subsequent removal. A study was 
conducted where filters were placed before surgery and removed 4 weeks 
postoperatively. There was no fatal PE or deaths.  
ORTHOPEDIC PATIENTS 
      Orthopaedic surgeries such as total hip arthroplasty, total knee arthroplasty, 
lower extremity fracture repair. The incidence of PE in patients not receiving 
prophylaxis was 60 to 70%. The filters were placed perioperatively. Optional 
filters are used in high risk period and are retrieved when the risk for 
thromboembolism is less. Morbidity was minimal in filter prophylaxis. The 
retrievable filter placement was suggested an adjunct to the standard prophylaxis 
in high risk orthopaedic patients. Thus the retrievable filters are preserved in 
patients where anticoagulation prophylaxis is contraindicated. 
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CANCER PATIENTS 
Malignancy poses a great risk for venous thromboembolism development. Even 
with anticoagulant prophylaxis the risk was found to be high. In patients with a 
previous history of thromboembolism, there is increased chance of recurrence 
after the development of new metastasis or neutropenia. Cancer patients are also 
at increased risk of bleeding despite anticoagulation. Vena cava filters is an 
alternative to long term anticoagulant in a subgroup of patients with increased 
risk of recurrence. The filter placement is based on the survival. In brain tumour 
patients filter placements are not cost effective. But in breast cancer patients vena 
cava filter placement is more cost effective than anticoagulation. In patients with 
advanced stages of malignancy, filter placement is of little clinical significance. 
The filters should be reserved for patients with documented venous 
thromboembolism because of the potential for increased thrombotic events. 
HIGH RISK GENERAL SURGICAL PATIENTS 
   The risk of venous thromboembolism is high in patients with increased risk of 
malignancy, obesity, varicose veins and oestrogen use, type of anaesthesia (high 
risk with general anaesthesia). Perioperative factors such as degree of 
mobilization, fluid status, and transfusion practices. Shorter duration of 
prophylaxis may increase the risk of venous thromboembolism. After major 
general surgery DVT’s develop within 1 to 2 weeks. Thus postoperative 
anticoagulants are given up to 28 days in high risk patients. Uses of prophylactic 
filters are an attractive option. These filters have an advantage of decreased 
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bleeding risk. Vena cava filter use is limited to standard indication for 
documented venous thromboembolism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
98 
 
Results  
One patient out of 30 had asymptomatic DVT on 7th POD  on left leg. The 
patient is 25 yrs old female, her operation time 1-2 hours, and mobilised early < 
24 hrs with no obvious risk factors.  
She was further evaluated. 
Repeat LFT – normal, PT/INR – normal, complete hemogram with ESR – 
normal, BT/CT – normal, Rheumatoid Factor – negative, 
She was started on LMWH along with warfarin. Her INR was maintained around 
1-2.  Again she underwent Doppler on 12th POD and on 17th POD and found to 
be normal.  
The patient was referred to Madras Medical College, Vascular surgery 
department for further work up and management.  
She came for follow up after a month time to our OP. she was evaluated there at 
vascular surgery and found every thing normal. Now she is doing well. 
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Statistical analysis 
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Conclusion 
The patients who had indications for cholecystectomy, and had undergone 
surgery, who otherwise had no risk factors for DVT, developed DVT with the 
incidence of 1/30 in our hospital. 
In my study, I have excluded all the DVT risk patients.  
But the sample size and its representation about various population groups are 
not adequate. So with this experience further studies are to be done.  
So it is better to start some form of mechanical method of prophylaxis to all 
patients undergoing cholecystectomy, as the immobilisation is expected from 
pain due to upper abdomen incision, obesity, females and other risk factors, then 
according to post operative clinical findings and investigations if any is positive 
for DVT, further management is to be done. 
Because cholecystectomy is done for patients are also found to have risk factors 
for DVT as it is shared by both. 
In the presence of some risk factors for DVT, the patient should be started on 
pharmacological method of prophylaxis. 
But ultimately, all the patients undergoing cholecystectomy should be given the 
basic measures like adequate hydration, adequate analgesia, and identification of 
risk factors, early ambulation, both active and passive flexion exercises and 
proper information to patients on the clinical presentation of DVT. 
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